T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alcon
ALC
|
+$2.11B |
| 2 |
Linde
LIN
|
+$1.34B |
| 3 |
American International
AIG
|
+$1.34B |
| 4 |
Marvell Technology
MRVL
|
+$1.28B |
| 5 |
TSS
Total System Services, Inc.
TSS
|
+$1.24B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$2.27B |
| 2 |
Eli Lilly
LLY
|
+$1.64B |
| 3 |
NVIDIA
NVDA
|
+$1.59B |
| 4 |
RHT
Red Hat Inc
RHT
|
+$1.55B |
| 5 |
Booking.com
BKNG
|
+$1.12B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.88% |
| 2 | Healthcare | 16.96% |
| 3 | Financials | 13.79% |
| 4 | Consumer Discretionary | 13.57% |
| 5 | Industrials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZN
1276
DELISTED
Horizon Global Corporation
HZN
| $12.5M | ﹤0.01% |
3,487,928
+404,930
| +13% | +$1.32M |
|
|
POLY
1277
DELISTED
Plantronics, Inc.
POLY
| $12.5M | ﹤0.01% |
337,013
-65,794
| -16% | -$3.05M |
|
1278
BHP
BHP
$222B
| $12.5M | ﹤0.01% |
240,410
-8,083
| -3% | -$390K |
|
1279
Copa Holdings
CPA
$6.17B
| $12.5M | ﹤0.01% |
127,720
-11,662
| -8% | -$1.03M |
|
1280
Macy's
M
$6.27B
| $12.4M | ﹤0.01% |
579,083
+460
| +0.1% | +$10.5K |
|
1281
Moderna
MRNA
$25.4B
| $12.2M | ﹤0.01% |
835,427
+15,652
| +2% | +$336K |
|
1282
Crinetics Pharmaceuticals
CRNX
$8.96B
| $12.2M | ﹤0.01% |
487,916
+1,786
| +0.4% | +$44.2K |
|
1283
Qiagen
QGEN
$8.93B
| $12M | ﹤0.01% |
279,141
+37,492
| +16% | +$1.55M |
|
1284
Newell Brands
NWL
$2.63B
| $12M | ﹤0.01% |
777,459
-153,513
| -16% | -$2.3M |
|
1285
AngioDynamics
ANGO
$647M
| $12M | ﹤0.01% |
607,751
+129,497
| +27% | +$2.64M |
|
1286
H&R Block
HRB
$6.76B
| $11.8M | ﹤0.01% |
403,992
+9,820
| +2% | +$264K |
|
|
ARQL
1287
DELISTED
Arqule Inc
ARQL
| $11.8M | ﹤0.01% |
+1,070,010
| New | +$7.45M |
|
1288
Bread Financial
BFH
$4.51B
| $11.7M | ﹤0.01% |
104,941
-613
| -0.6% | -$74.1K |
|
|
STML
1289
DELISTED
Stemline Therapeutics, Inc.
STML
| $11.6M | ﹤0.01% |
759,365
-133,221
| -15% | -$1.93M |
|
1290
Innoviva
INVA
$1.5B
| $11.6M | ﹤0.01% |
797,849
-221
| -0% | -$3.13K |
|
|
PBCT
1291
DELISTED
People's United Financial Inc
PBCT
| $11.5M | ﹤0.01% |
687,441
+18,443
| +3% | +$306K |
|
|
HBI
1292
DELISTED
Hanesbrands
HBI
| $11.3M | ﹤0.01% |
654,860
| – | – |
|
1293
Boot Barn
BOOT
$4.92B
| $11.2M | ﹤0.01% |
315,115
-210,814
| -40% | -$6.35M |
|
1294
Kinross Gold
KGC
$31.9B
| $11.2M | ﹤0.01% |
2,884,336
+2,849,336
| +8,141% | +$9.6M |
|
|
AGFS
1295
DELISTED
AgroFresh Solutions Inc
AGFS
| $11.2M | ﹤0.01% |
7,384,111
| – | – |
|
1296
Stoke Therapeutics
STOK
$2.02B
| $11M | ﹤0.01% |
+376,900
| New | +$10.1M |
|
1297
Cooper-Standard Automotive
CPS
$484M
| $11M | ﹤0.01% |
239,167
-187
| -0.1% | -$8.92K |
|
1298
Ranger Energy Services
RNGR
$405M
| $10.9M | ﹤0.01% |
1,353,004
| – | – |
|
1299
Quanta Services
PWR
$101B
| $10.9M | ﹤0.01% |
284,667
+4,087
| +1% | +$155K |
|
|
FOLD
1300
DELISTED
Amicus Therapeutics
FOLD
| $10.8M | ﹤0.01% |
864,581
+1,236
| +0.1% | +$15.7K |
|
Similar funds
T. Rowe Price Associates's Q2 2019 Portfolio in Review
As of Q2 2019, T. Rowe Price Associates held 2,600 positions worth $712B, up 4.7% from $680B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
T. Rowe Price Associates's Q2 2019 filing shows 72 new, 1,394 increased, 949 reduced and 59 closed positions. Its largest new stake was Alcon: 36,020,796 shares worth $2.23B. The largest sale was UnitedHealth, an estimated $2.27B.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2019 buy was Alcon: 36,020,796 shares worth $2.23B.
- T. Rowe Price Associates added most to Linde in Q2 2019, an estimated $1.34B increase.
- T. Rowe Price Associates's biggest Q2 2019 reduction was UnitedHealth, cutting an estimated $2.27B.
- T. Rowe Price Associates fully exited Ultimate Software Group Inc in Q2 2019, selling an estimated $609M.
- T. Rowe Price Associates's ten largest holdings make up 21% of its $712B portfolio in Q2 2019.
- T. Rowe Price Associates opened 72 new positions and closed 59 in Q2 2019.
- T. Rowe Price Associates's portfolio value rose 4.7% quarter-over-quarter to $712B.
Based on T. Rowe Price Associates's 13F filing for Q2 2019, filed 15 Aug 2019.